Loading...
Please wait, while we are loading the content...
Similar Documents
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
| Content Provider | Scilit |
|---|---|
| Author | Leong, Steven R. Sukumaran, Siddharth Hristopoulos, Maria Totpal, Klara Stainton, Shannon Lu, Elizabeth Wong, Alfred Tam, Lucinda Newman, Robert Vuillemenot, Brian R. Ellerman, Diego Gu, Chen Mathieu, Mary Dennis, Mark S. Nguyen, Allen Zheng, Bing Zhang, Crystal Lee, Genee Chu, Yu-Waye Prell, Rodney A. Lin, Kedan Laing, Steven T. Polson, Andrew G. |
| Copyright Year | 2017 |
| Description | Key Points Bispecific antibodies binding CD3 and CLL-1 deplete CLL-1+ target cells in animal models. An appropriately engineered CLL-1/CD3 bispecific antibody could be effective in treating AML. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290988/pdf |
| Ending Page | 618 |
| Page Count | 10 |
| Starting Page | 609 |
| DOI | 10.1182/blood-2016-08-735365 |
| Journal | Blood |
| Issue Number | 5 |
| Volume Number | 129 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2017-02-02 |
| Access Restriction | Open |
| Subject Keyword | Research and Experimental Medicine Cll Bispecific Antibody Treatment Target Cells Acute Myeloid Treating Aml Appropriately Engineered Myeloid Leukemia Journal: Blood (Vol- 84, Issue- 5) |
| Content Type | Text |
| Resource Type | Article |